Debra A Bell
Affiliation: Massachusetts General Hospital
- Origins and molecular pathology of ovarian cancerDebra A Bell
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Mod Pathol 18:S19-32. 2005....
- Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancerZhenfeng Duan
Division of Hematology Oncology, Department of Pathology, and Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Clin Cancer Res 12:5055-63. 2006..To further clarify the significance of Stat3 activation in ovarian cancer, here we investigated the Stat3 expression and activation in ovarian cancer and ovarian cancer multidrug resistance cell lines...
- Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinomaSarah E Rollins
James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Boston, MA 02114, USA
Am J Surg Pathol 30:457-62. 2006....
- Psammoma bodies in cervicovaginal cytology specimens: a clinicopathological analysis of 31 casesJoseph Misdraji
Department of Pathology and Cytopathology Laboratory, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
Gynecol Oncol 103:238-46. 2006..Psammoma bodies in cervicovaginal cytology specimens are associated with malignant and benign conditions. Few studies have evaluated which features distinguish patients with underlying malignancy from those with benign conditions...
- Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomasColleen M Feltmate
Department of Obstetrics, Gynecology, and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
Clin Cancer Res 11:7651-7. 2005..The purpose of this study is to identify molecular biomarkers for mucinous ovarian adenocarcinoma and compare them with those of appendiceal origin...
- Current issues in the pathology of ovarian cancerJoseph T Rabban
Gillette Center in Women s Cancer Pathology and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
J Reprod Med 50:467-74. 2005..Special processing of the pathologic specimens is required to detect early and minimal neoplasia in this setting. These current issues in the pathology of ovarian carcinoma and their clinical significance form the basis of this review...
- Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectivesDebra A Bell
Department of Pathology, Massachusetts General Hospital, Boston 02114 2696, USA
Hum Pathol 35:934-48. 2004....
- Superficial endometriosis of the cervix: A source of abnormal glandular cells on cervicovaginal smearsWanda M Szyfelbein
James Homer Wright Pathology Laboratories of the Massachusetts General Hospital, Department of Pathology, Harvard Medical School, Boston, MA 02114, USA
Diagn Cytopathol 30:88-91. 2004..However, the cytologic features of endometriosis show sufficient overlap with those of precancerous and cancerous glandular lesions that many of these cases will continue to be diagnosed as "atypical glandular cells."..
- Classification of benign endometrial glandular cells in cervical smears from postmenopausal womenEdi Brogi
Department of Pathology, Cytology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Cancer 96:60-6. 2002..However, PMP women on hormone replacement therapy (HRT) sometimes may experience endometrial shedding. The significance of such a finding has not been investigated in detail...
- Borderline ovarian tumors: key points and workshop summarySteven G Silverberg
Department of Pathology, University of Maryland School of Medicine, Baltimore 21201, USA
Hum Pathol 35:910-7. 2004....
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2004. A 52-year-old woman with postmenopausal bleeding and a cystic ovarian massRichard T Penson
Cancer Center, Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, USA
N Engl J Med 351:2531-8. 2004
- Molecular pathogenesis and therapeutic targets in epithelial ovarian cancerJeremy R Chien
Department of Experimental Pathology, Mayo Clinic, Rochester, Minnesota, USA
J Cell Biochem 102:1117-29. 2007..Finally, we will discuss advances and new challenges in the development of mouse model systems to investigate EOC precursor lesions, progression, metastasis, and chemoresistance...